Cheng Liu PhD

Dr. Cheng Liu is the Founder, President, and CEO of Eureka Therapeutics. Before founding Eureka, he was a Principal Scientist in antibody drug discovery at Chiron (now Novartis). With over 20 years of experience in the field, Dr. Liu holds more than 500 patents and published patent applications, of which over 100 patents have issued worldwide, and has authored numerous peer-reviewed papers on cancer immunotherapy.

Dr. Liu is the inventor of multiple first-in-class, clinical-stage cancer drugs against various tumor targets, including drugs targeting CSF1 for the treatment of bone metastasis, BCMA for multiple myeloma, and AFP and GPC3 for liver cancer. In 2007, he was awarded Special U.S. Congressional Recognition for his contributions to improving human health. Dr. Liu is the editor of the book “Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development”. Dr. Liu received his B.S. in Cell Biology and Genetics from Peking University and a Ph.D. in Molecular Cell Biology from the University of California, Berkeley.